MedTrace Logo

In Vivo Mass Balance Study of [14C]Hemay005

NCT05468645 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-02-29

No results posted yet for this study

Summary

This study is a single-center, single-dose, non-randomized, open-label study to evaluate the in vivo mass balance of \[14C\]Hemay005. Six healthy male subjects are planned to be enrolled.

Conditions

  • Health Volunteer

Interventions

DRUG

[14C]Hemay005

Name: \[14C\]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.

Sponsors & Collaborators

  • Ganzhou Hemay Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • YanMei Liu · Shanghai Xuhui District Central Hospital

  • GangYi Liu · Shanghai Xuhui District Central Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2022-09-01
Completion
2022-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05468645 on ClinicalTrials.gov